Last reviewed · How we verify
Crizanlizumab Injection
Crizanlizumab is a monoclonal antibody that binds to P-selectin on the surface of platelets and endothelial cells, blocking platelet-endothelial interactions and reducing vaso-occlusive crises in sickle cell disease.
Crizanlizumab is a monoclonal antibody that binds to P-selectin on the surface of platelets and endothelial cells, blocking platelet-endothelial interactions and reducing vaso-occlusive crises in sickle cell disease. Used for Sickle cell disease (reduction of vaso-occlusive crises in patients 16 years and older).
At a glance
| Generic name | Crizanlizumab Injection |
|---|---|
| Sponsor | Matthew Neal MD |
| Drug class | P-selectin inhibitor monoclonal antibody |
| Target | P-selectin |
| Modality | Small molecule |
| Therapeutic area | Hematology/Oncology |
| Phase | FDA-approved |
Mechanism of action
P-selectin is an adhesion molecule that mediates the interaction between platelets, red blood cells, and endothelial cells, contributing to vaso-occlusive events in sickle cell disease. By blocking P-selectin, crizanlizumab reduces the adhesion of sickle cells to the endothelium and decreases platelet activation, thereby reducing the frequency and severity of vaso-occlusive crises. This mechanism addresses a key pathophysiological process in sickle cell disease without directly affecting hemoglobin polymerization.
Approved indications
- Sickle cell disease (reduction of vaso-occlusive crises in patients 16 years and older)
Common side effects
- Headache
- Nausea
- Pyrexia
- Infusion-related reactions
- Arthralgia
Key clinical trials
- Crizanlizumab Alone or in Combination With Nivolumab for Glioblastoma and Melanoma With Brain Metastases (PHASE2)
- Accelerating COVID-19 Therapeutic Interventions and Vaccines 4 ACUTE (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Crizanlizumab Injection CI brief — competitive landscape report
- Crizanlizumab Injection updates RSS · CI watch RSS
- Matthew Neal MD portfolio CI